Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
5 search results for:

Octreotide 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 29-01-2018 | FDA | News | Article
    approvalsWatch

    Lutetium-177–dotatate granted US approval for GEP-NETs

    The US FDA granted approval for the treatment following a randomized clinical trial in 229 patients that demonstrated extended progression-free survival with 177 Lu–dotatate plus octreotide versus octreotide alone.

  2. 12-01-2017 | Neuroendocrine tumors | News | Article
    News in brief

    OS promise for 177Lu-dotatate in neuroendocrine tumors

    A prespecified interim analysis of the NETTER-1 trial suggests that treatment with lutetium-177–dotatate could prolong overall survival relative to high-dose octreotide long-acting repeatable in patients with metastatic midgut neuroendocrine tumors.

  3. 01-09-2017 | Neuroendocrine tumors | Article

    Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30

    In this study, the authors find peptide receptor radionuclide therapy to be effective in the treatment of pancreatic neuroendocrine tumors whilst also improving the quality of life of patients. Marinova M, et al. Eur J Nucl Med Mol Imaging 2017. doi:10.1007/s00259-017-3816-z

  4. 17-08-2017 | EMA | Drug approval | Article
    approvalsWatch

    Multiple orphan medications get nod from EMA

    The decision is based on results showing improved progression-free survival with 177 Lu-oxodotreotide over the somatostatin receptor agonist octreotide LAR in this patient population. --- The committee has recommended granting a marketing authorization to avelumab for the treatment of adults with metastatic Merkel cell carcinoma.

  5. 01-09-2016 | Neuroendocrine tumors | Book chapter | Article

    Targeted therapies for neuroendocrine neoplasms

    In this chapter, Soares and Strosberg describe the currently available targeted therapies for neuroendocrine tumors and review the clinical status of promising investigational therapies. Soares HP & Strosberg J. In:  Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances . Edited by Nasir A & Coppola D. Springer New York, 2016. doi:10.1007/978-1-4939-3426-3_28

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.